The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review
Introduction: Given the emergence of combination of programmed cell death protein-1 and CTLA4 pathway blockade as effective treatment options in malignant pleural mesothelioma (MPM), there is interest in the extent to which programmed death-ligand 1 (PD-L1) expression may be prognostic of clinical o...
Main Authors: | Aaron S. Mansfield, MD, Rebecca J. Brown, PhD, Cormac Sammon, PhD, Melinda J. Daumont, PhD, Mike McKenna, MSc, Jenine K. Sanzari, PhD, Patrick M. Forde, MD |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-05-01
|
Series: | JTO Clinical and Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266636432200039X |
Similar Items
-
Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma
by: Robert A. Belderbos, MD, et al.
Published: (2021-04-01) -
Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
by: Nobukazu Fujimoto, MD, PhD, et al.
Published: (2021-03-01) -
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma
by: Suna Sun, MD, et al.
Published: (2022-12-01) -
Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
by: Kazuhiko Nakagawa, MD, PhD, et al.
Published: (2021-06-01) -
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
by: Roger Y. Kim, MD, et al.
Published: (2021-06-01)